Medtronic (NYSE:MDT – Get Free Report) and IRIDEX (NASDAQ:IRIX – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.
Analyst Ratings
This is a summary of recent recommendations and price targets for Medtronic and IRIDEX, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medtronic | 1 | 9 | 18 | 0 | 2.61 |
| IRIDEX | 1 | 0 | 1 | 0 | 2.00 |
Medtronic currently has a consensus target price of $102.88, suggesting a potential upside of 0.04%. IRIDEX has a consensus target price of $3.00, suggesting a potential upside of 332.90%. Given IRIDEX’s higher possible upside, analysts clearly believe IRIDEX is more favorable than Medtronic.
Profitability
This table compares Medtronic and IRIDEX’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medtronic | 13.93% | 14.78% | 7.97% |
| IRIDEX | -6.88% | N/A | -12.55% |
Institutional & Insider Ownership
82.1% of Medtronic shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 0.3% of Medtronic shares are owned by insiders. Comparatively, 8.6% of IRIDEX shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Medtronic has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, IRIDEX has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
Earnings and Valuation
This table compares Medtronic and IRIDEX”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medtronic | $36.36 billion | 3.62 | $4.80 billion | $4.06 | 25.33 |
| IRIDEX | $52.67 million | 0.23 | -$4.44 million | ($0.20) | -3.46 |
Medtronic has higher revenue and earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.
Summary
Medtronic beats IRIDEX on 11 of the 14 factors compared between the two stocks.
About Medtronic
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
About IRIDEX
IRIDEX Corporation (NASDAQ: IRIX) develops, manufactures and sells laser-based medical systems and disposable devices used in ophthalmic procedures. Its technologies are designed to help eye-care professionals treat glaucoma, retinal diseases and other conditions affecting vision. The company’s product portfolio includes the Cyclo Glaucoma Laser System, which uses MicroPulse and continuous-wave laser technology for glaucoma treatment, as well as laser systems such as the IRIDEX IQ series for retinal and photocoagulation procedures.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
